SBIR Phase II: Development of Agents to Promote Cellular Ga-67 (Gallium-67) Uptake

SBIR 第二阶段：开发促进细胞 Ga-67 (Gallium-67) 吸收的药物

• 批准号: 0450618
• 负责人: Takuji Tsukamoto
• 金额: --
• 依托单位: Chemica Technologies Inc
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-10-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0450618&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Development; Agents

This Small Business Innovation Research Phase II project focuses on the development of new pharmaceutical agents to selectively enhance tumor imaging using gallium 67. A photo-degradation product of nifedipine, nitrosipine, has been found to selectively enhance the uptake of Ga67 by tumor cells. A specific derivative of nitrosipine has an even better selective uptake of the radioactive imaging agent. This project will synthesize and test other nitrosipine derivatives and determine the efficacy of Ga67 uptake in animal models using these complexing agents.The commercial application of this technology is in the area of diagnostic imaging. The use of Ga67 in tumor imaging is currently very limited due to poor selectivity of the agent for tumor cells. Enhanced uptake in tumor cells relative to normal cells would expand the types of tumors that could be effectively imaged and possibly replace the more costly and complex PET scan imaging using radioactive fluorinated sugars.

这个小型企业创新研究二期项目的重点是开发新的药物制剂，以选择性地增强使用镓67的肿瘤成像。硝苯地平的一种光降解产物，亚硝基嗪，已被发现选择性地增强肿瘤细胞对Ga67的摄取。亚硝基哌嗪的特定衍生物对放射性显像剂具有更好的选择性吸收。本项目将合成和测试其他亚硝基平衍生物，并确定使用这些络合剂在动物模型中摄取Ga67的功效。这项技术的商业应用是在诊断成像领域。由于Ga67对肿瘤细胞的选择性较差，目前在肿瘤成像中的应用非常有限。与正常细胞相比，肿瘤细胞摄取的增强将扩大可有效成像的肿瘤类型，并可能取代使用放射性氟化糖的更昂贵和复杂的PET扫描成像。